药康生物 - Financials

药康生物 — Financial Statements

Annual Quarterly

5 10 All

Income Statement

Balance Sheet

Cash Flow

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020	FY 2019Dec 31, 2019	FY 2018Dec 31, 2018
+Revenue	687.0M	622.0M	517.0M	394.0M	262.0M	193.0M	53.3M
Revenue Growth %	10.5%	20.3%	31.2%	50.4%	35.8%	262.2%	--
Total Revenue	687.0M	622.0M	517.0M	394.0M	262.0M	193.0M	53.3M
Cost Of Revenue	261.0M	202.0M	148.0M	101.0M	73.2M	63.9M	16.9M
+Gross Profit	426.0M	420.0M	369.0M	293.0M	188.8M	129.1M	36.4M
Gross Margin %	62.0%	67.5%	71.4%	74.4%	72.0%	66.9%	68.2%
Total Operating Cost	605.0M	517.0M	414.0M	311.0M	215.0M	171.0M	64.5M
Selling Expenses	107.0M	82.2M	76.3M	53.5M	28.8M	30.2M	5.8M
Admin Expenses	133.0M	117.0M	98.4M	81.0M	50.7M	40.2M	27.4M
Rd Expenses	87.1M	96.6M	82.9M	55.2M	48.2M	30.3M	10.5M
Finance Expenses	-11.6M	-14.2M	-15.1M	-2.3M	759,100	218,000	-41,300
+Operating Income	119.0M	164.0M	174.0M	143.0M	91.5M	46.9M	-1.7M
Operating Margin %	17.3%	26.4%	33.7%	36.3%	34.9%	24.3%	-3.1%
Non Operating Income	14,000	7,600	3.00	49,800	52,500	3,000	0.00
Non Operating Expenses	166,800	2.4M	271,800	66.00	214,800	20,200	--
Investment Income	8.0M	11.5M	9.5M	11.1M	7.1M	3.3M	--
Fair Value Change Income	2.3M	2.7M	-45,700	319,800	--	177,100	24,900
Asset Disposal Income	12,500	-17,200	-100,900	--	--	--	--
Asset Impairment Loss	21.6M	21.7M	15.3M	14.1M	9.2M	3.5M	3.7M
Other Income	27.3M	44.5M	62.3M	49.1M	37.4M	21.9M	9.6M
Income Before Tax	119.0M	161.0M	174.0M	143.0M	91.4M	46.9M	-1.7M
Income Tax	9.4M	2.4M	9.0M	18.4M	14.9M	12.1M	4.4M
+Net Income	110.0M	159.0M	165.0M	125.0M	76.4M	34.7M	-6.0M
Net Margin %	16.0%	25.6%	31.9%	31.7%	29.2%	18.0%	-11.3%
Net Income Attributable	110.0M	159.0M	165.0M	125.0M	76.4M	34.7M	-6.0M
Minority Interest	--	--	--	--	--	-10,100	-12,800
Eps Basic	0.27	0.39	0.42	0.35	0.21	--	--
Eps Diluted	0.27	0.39	0.42	0.35	0.21	--	--

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020	FY 2019Dec 31, 2019	FY 2018Dec 31, 2018
Cash And Equivalents	701.0M	560.0M	422.0M	294.0M	524.0M	222.0M	23.2M
Trading Financial Assets	467.0M	638.0M	791.0M	206.0M	--	26.9M	30.0M
Accounts Receivable	351.0M	269.0M	185.0M	119.0M	90.7M	63.5M	29.6M
Notes Receivable	--	--	236,800	--	--	--	--
Notes And Accounts Receivable	351.0M	269.0M	185.0M	119.0M	90.7M	63.5M	29.6M
Prepayments	4.6M	3.9M	2.8M	2.0M	1.7M	779,300	399,100
Inventory	54.2M	47.1M	49.5M	30.1M	17.3M	12.4M	13.9M
Total Current Assets	1.7B	1.7B	1.5B	707.0M	647.0M	329.0M	100.0M
Long Term Equity Investment	80.0M	69.2M	68.5M	30.1M	--	--	--
Fixed Assets	--	487.0M	194.0M	176.0M	160.0M	5.3M	701,100
Fixed Assets Total	493.0M	487.0M	194.0M	176.0M	160.0M	5.3M	701,100
Construction In Progress	--	89.6M	172.0M	53.0M	2.9M	17.4M	914,200
Construction In Progress Total	90.9M	89.6M	172.0M	53.0M	2.9M	17.4M	914,200
Intangible Assets	49.0M	47.3M	48.5M	49.5M	41.2M	22.0M	558,100
Long Term Deferred Expenses	34.2M	36.7M	19.3M	24.6M	23.8M	4.0M	191,300
Total Non Current Assets	863.0M	920.0M	787.0M	347.0M	236.0M	59.1M	4.3M
Total Assets	2.6B	2.6B	2.3B	1.1B	883.0M	388.0M	105.0M
Short Term Borrowings	88.0M	76.2M	12.2M	5.2M	5.0M	16.0M	2.0M
Accounts Payable	72.2M	102.0M	50.8M	61.7M	41.3M	23.2M	26.7M
Advance Receipts	--	--	--	--	--	49.5M	21.4M
Contract Liabilities	138.0M	108.0M	89.2M	75.9M	60.0M	--	--
Total Current Liabilities	371.0M	366.0M	214.0M	192.0M	149.0M	123.0M	61.7M
Long Term Borrowings	--	--	--	20.0M	--	--	--
Total Non Current Liabilities	66.7M	86.5M	61.9M	77.0M	76.5M	24.2M	14.9M
Total Liabilities	438.0M	453.0M	276.0M	269.0M	226.0M	148.0M	76.6M
Paid In Capital	410.0M	410.0M	410.0M	360.0M	360.0M	11.6M	10.0M
Capital Reserve	1.3B	1.3B	1.3B	277.0M	274.0M	200.0M	23.8M
Surplus Reserve	52.3M	43.6M	32.3M	18.8M	4.5M	4.6M	--
Retained Earnings	435.0M	412.0M	281.0M	130.0M	19.2M	24.1M	-6.0M
Minority Equity	--	--	--	--	--	--	337,200
Equity Attributable	2.1B	2.1B	2.0B	786.0M	657.0M	240.0M	27.7M
Total Equity	2.1B	2.1B	2.0B	786.0M	657.0M	240.0M	28.1M

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020	FY 2019Dec 31, 2019	FY 2018Dec 31, 2018
Cash From Sales	651.0M	559.0M	460.0M	387.0M	252.0M	196.0M	49.9M
Tax Refunds Received	--	10.9M	22.5M	--	--	--	--
Total Operating Cash Inflow	674.0M	627.0M	558.0M	430.0M	344.0M	229.0M	74.6M
Cash Paid For Goods	134.0M	122.0M	109.0M	75.6M	56.2M	68.1M	7.6M
Cash Paid To Employees	307.0M	269.0M	220.0M	143.0M	82.6M	61.4M	13.7M
Taxes Paid	40.6M	14.3M	25.7M	27.3M	18.8M	8.0M	1.1M
Total Operating Cash Outflow	584.0M	511.0M	452.0M	316.0M	214.0M	164.0M	31.2M
Operating Cash Flow	90.3M	117.0M	106.0M	113.0M	130.0M	65.1M	43.4M
Total Investing Cash Inflow	1.9B	2.0B	792.0M	1.5B	1.7B	517.0M	--
Total Investing Cash Outflow	1.8B	2.0B	1.8B	1.9B	1.9B	557.0M	32.5M
Investing Cash Flow	159.0M	-18.6M	-995.0M	-354.0M	-133.0M	-40.3M	-32.5M
Cash From Borrowings	98.0M	86.0M	12.0M	25.0M	22.0M	16.0M	2.0M
Dividends And Interest Paid	80.1M	17.9M	283,500	680,000	672,300	235,800	6,100
Debt Repayments	86.0M	22.0M	25.0M	10.7M	28.0M	2.0M	--
Total Financing Cash Inflow	98.0M	86.0M	1.1B	25.0M	335.0M	176.0M	12.3M
Total Financing Cash Outflow	207.0M	46.7M	41.6M	14.8M	28.7M	2.2M	6,111
Financing Cash Flow	-109.0M	39.3M	1.0B	10.2M	306.0M	174.0M	12.3M
Net Change In Cash	141.0M	138.0M	128.0M	-231.0M	302.0M	199.0M	23.2M
Ending Cash Balance	701.0M	560.0M	422.0M	294.0M	524.0M	222.0M	23.2M
Capex	114.0M	206.0M	190.0M	89.1M	167.0M	45.7M	2.5M